Gilead Sciences, a biopharmaceutical company, focuses its investment strategy on expanding its therapeutic areas, particularly in oncology and inflammation, while maintaining its leadership in antivirals. This involves significant investment in internal research and development, including AI-enabled labs and advanced manufacturing, alongside strategic mergers, acquisitions, and collaborations with other biotechnology companies to strengthen its pipeline and bring innovative therapies to market.
67% of their portfolio is in Healthcare. Their most common stage is series-b (67% of deals). Average disclosed round size is $45.0M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
Top Co-Investors
Polaris Venture Partners1 shared
Hopu Investments1 shared
Invus1 shared
Bill & Melinda Gates Foundation1 shared
GGV Capital1 shared
Industry Ventures1 shared
aCrew1 shared
World Innovation Lab1 shared
Positive Sum1 shared
Bold Capital Partners1 shared
Xfund1 shared
Gaingels1 shared
Last updated: 16 April 2026